CARNA BIOSCIENCES

News Release

November 6, 2023
Carna Biosciences, Inc.

Carna announces acceptance of two posters on AS-1763 for presentation at ASH Annual Meeting

Carna Biosciences, a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, today announces that two posters on AS-1763 preclinical study results and ongoing clinical study design will be presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

The posters will be featuring the preclinical characterization of AS-1763 and its Phase 1b study design. AS-1763, an investigational small molecule drug designed to non-covalently inhibit Bruton's tyrosine kinase (BTK) in a highly selective manner, is currently under development for the treatment of patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies who have developed resistance or are intolerant to at least two prior lines of systemic therapy including a covalent BTK inhibitor. The preclinical findings will be presented by Shady I. Tantawy, MD, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center and Carna scientists. The clinical study design will be presented by Nitin Jain, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center and all the other principal investigators at the participating clinical sites. The ASH Annual Meeting and Exposition will take place December 9-12, 2023, in San Diego, California.

Presentation Details

Publication Number: 1453

Poster title:	Characterization and Preclinical Evaluation of AS-1763, an Oral, Potent and Selective Noncovalent BTK inhibitor, in Chronic Lymphocytic Leukemia
Session:	605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I
Session date:	December 9, 2023
Presenter:	Shady I. Tantawy[1], Natalia Timofeeva[1], Hitomi Fujiwara[2], Mariko Hatakeyama[2], Breana Herrea[1], Lizbeth Loza[1], Tokiko Asami[2], Hiroshi Ohmoto[2], Kyoko Miyamoto[3], Yu Nishioka[2], Akinori Arimura[3], Masaaki Sawa[2], Nitin Jain[1], Varsha Gandhi[1,]

[1]University of Texas MD Anderson Cancer Center, Houston, TX;[2]Carna Biosciences, Inc.;[3]CarnaBio USA, Inc.

The abstract is now available at:

URL: https://ash.confex.com/ash/2023/webprogram/Paper189659.html

Publication Number: 3288

Poster title:	Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Session:	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
Session date:	December 10, 2023
Presenter:	Nitin Jain[1], James D'Olimpio[2], Andrew Gillis-Smith[3], Seung Tae Lee[4], Nirav N. Shah[5], Javier Pinilla-Ibarz[6], Catherine Coombs[7], Jacqueline Barrientos[8], Shuo Ma[9], Masaaki Sawa[10], Kyoko Miyamoto[11], Akinori Arimura[10,11], Varsha Gandhi[1], and William G. Wierda[1]

[1]University of Texas MD Anderson Cancer Center, Houston, TX; [2]Clinical Research Alliance, Westbury, NY; [3]UMass Chan Medical School / UMass Memorial Medical Center, Worcester, MA; [4]University of Maryland Medical Center, Baltimore, MD; [5]Medical College of Wisconsin, Milwaukee, WI; [6]Moffitt Cancer Center, Tampa, FL; [7]University of California Irvine Health, Irvine, CA; [8]Mount Sinai Medical Center, Miami Beach, FL; [9]Northwestern University, Chicago, IL; [10]Carna Biosciences, Inc., Kobe, Japan; [11]CarnaBio USA, Inc., South San Francisco, CA

The abstract is now available at:

URL: https://ash.confex.com/ash/2023/webprogram/Paper182568.html

About AS-1763

AS-1763 is a highly selective, orally bioavailable, non-covalent inhibitor of both the wild type and mutant BTKs for the treatment of CLL and other B cell malignancies. Covalent BTK inhibitors including ibrutinib are key therapeutic options for patients with B cell malignancies. However, patients are reported to develop resistance during the treatment due to substitution of cysteine residue at 481 position with serine (C481S mutation) in BTK, which reduces the efficacy of the covalent BTK inhibitors. In addition, the emergence of other types of resistance mutations to non-covalent BTK inhibitors including pirtobrutinib have been reported. AS-1763 potently inhibited both wild type and those mutant BTKs, strongly suggesting that AS-1763 will be a new therapeutic option for treating patients with B cell malignancies both having wild type and resistance mutations in BTK. Carna is advancing development of AS-1763 as a next-generation BTK inhibitor.

Contact:
Corporate Planning
Carna Biosciences, Inc.
TEL: +81-78-302-7075
https://www.carnabio.com/english/